A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was 'In patients undergoing lung resection for non-small cell lung cancer, is lymph node dissection or sampling superior?' Altogether 845 papers were found using the reported search, of which 14 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude that in stage I tumours there is little difference in survival when performing either mediastinal lymph node dissection (MLND) or lymph node sampling. However, survival is increased when performing MLND in stage II to IIIa tumours. Increased accuracy in staging is not observed with MLND. However, MLND reliably identifies more positive N2 nodes which may offer advantages in postoperative adjuvant treatment in more advanced disease.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
Three-part question
In [patients with non-small cell lung cancer] is [radical lymph node dissection or lymph node sampling] superior in terms of [survival and staging]?
Clinical scenario
You are about to undertake a right upper lobectomy for a stage Ia non-small cell lung cancer (NSCLC). You are deciding whether to undertake a complete mediastinal lymphadenectomy or lymph node sampling (LNS). 
Search strategy

Search outcome
Eight hundred and forty-five papers were found using the reported search. Of these 14 papers were selected following appraisal as they represented the highest level of evidence and the most recent updates of the subject. These are presented in Table 1 .
Results
This subject has previously been investigated by Barnard et al. [16] and this article represents an update of this previous work in light of significant recent development.
Survival
Wright et al. [2] performed a meta-analysis assessing the survival of patients undergoing lung resection for NSCLC combined with either mediastinal lymph node dissection (MLND) or LNS. In a pooled analysis of the three main randomised controlled trials (RCTs) at the time, the chance of survival over a four-year period was superior in patients who had MLND compared with LNS as the overall hazard ratio was 0.78 (95% CI 0.65-0.93; P = 0.005). In a Cochrane review, Manser et al. [3] The overall survival may therefore be affected by the stage of the tumour at the time of either LNS or MLND. Indeed only one RCT in the meta-analysis, Wu et al. [6] , showed a significant improvement in five-year survival for MLND over LNS for all stages of disease.
Izbicki et al. [7] did not observe a significant difference in survival when assessing resection of tumours of stages I to III combined. Also Passlick et al. [8] performed a prospective randomised trial of patients with stage I-IIIa undergoing MLND (n = 53) and LNS (n = 41) and found that there was no overall survival difference at five years between the two groups (P = 0.27).
Several studies assessed less advanced disease. Sugi et al. [9] failed to observe a significant difference in five-year survival rate in 115 patients with NSCLCs of < 2 cm in diameter undergoing MLND and LNS (81% and 84%, respectively). Similarly, Doddali et al. [10] performed a retrospective analysis of patients who underwent LNS (n = 207) and MLND (n = 258) for stage I NSCLC. They observed no significant difference in five-year survival (59.1% for LNS and 64.7% for MLND, P = 0.11). MLND was, however, a significant favourable prognostic indicator following the multivariate analysis (hazard ratio 1.429; P = 0.048).
Furthermore, Okada et al. [11] also reviewed patients with stage I NSCLC. The five-year overall survival for the LNS group (n = 377) and the MLND (n = 358) group was 83.2% and 79.7%, respectively. In the multivariate analysis, the type of dissection performed did not significantly affect either the disease-free survival (P = 0.636) or the overall survival (P = 0.119). Also, Gajra et al. [12] retrospectively analysed 442 patients undergoing lung resection for stage I disease. There was no significant difference between MLND and systematic LNS in terms of survival (85.9% and 83.3%, respectively). When assessing more advanced disease, Zhang et al. [13] followed up 219 patients with stage III NSCLC over five years. The median survival was 23.5 months in the MLND group and 20 months for the LNS group (P < 0.05). MLND was also a significant predictor of survival in the multivariate analysis.
Keller et al. [14] in a non-randomised comparison study observed patients with stage II and IIIa NSCLC. Median survival was 57.5 months for those patients who had undergone complete MLND (n = 186) and 29.2 months for those patients who had LNS (n = 187; P = 0.004).
Staging
When assessing staging accuracy, Keller et al. [14] observed that of the 186 who underwent complete MLND, 41% had N1 disease compared with 40% who underwent LNS (P = 0.92). N2 disease observed was also similar between MLND (N2 = 20%, N1 and N2 = 39%) and LNS (N2 only = 21%, N1 and N2 = 39%). However, among the 222 patients with N2 metastases, multiple levels of N2 disease were documented in 30% of patients who underwent complete MLND and in 12% of patients who had LNS (P = 0.001).
Izbicki et al. [15] conducted a RCT of 182 patients and showed a significant difference in the number of levels of lymph nodes involved. In those undergoing LNS 17.4% with N2 disease had multi-level nodal disease. This was compared to the MLND group with N2 disease where 57.2% were observed to have multilevel involvement (P = 0.007).
Clinical bottom line
We conclude that in stage I tumours there is little difference in survival when performing either MLND or LNS. We have read with great interest the paper of Hughes et al. [1] . Lymphnode staging during pulmonary resection for non small-cell lung cancer (NSCLC) has been greatly debated for some time. The present best evidence topic identifies a light advantage of mediastinal lymph-node dissection (MLND) compared to lymph node sampling (LNS) in respect of the rates of survival in stage II-IIIa. In addition, MLND is able to identify more multiple levels of N2 disease.
It is possible to derive some practical suggestions from the Hughes' study. Considering that the majority of patients requiring surgery for NSCLC lie in clinical stage I but some of them are shown to be understaged at pathological examination even in the 'PET era', it seems advisable to offer the advantages of MLND to all patients needing surgery.
A second point arises from everyday experience where a node judged negative at surgery may be shown to be metastatic at pathological examination and, conversely, a node considered positive during dissection may be shown to be negative at pathological examination. In this scenario, we believe that MLND is more effective in determining the real node staging in practical surgery.
Finally, it should be considered that research is progressing in molecular lymph-node staging and molecular technology could overtake the traditional hematoxylin-eosin in the near future [2] [3] [4] . Once again, MLND seems to be the only way to accurately collect the material for advanced lymph-node staging.
In conclusion, we thank Hughes and co-workers for highlighting the thin but important superiority of MLND compared to LNS. We hope that through MLND and precise detection of metastases (molecular staging), we may reach the definitive and correct stage for all patients affected by NSCLC.
